Penguin Jumps 14% on Earnings, Vistra Gains 8% on DOE Loan, Hess Falls 10% on Outlook Cut

Mumbai, 7 October 2026: US-listed stocks saw sharp moves on Wednesday as investors responded to a wide range of company-specific developments, including earnings results, raised guidance, strategic agreements, financing deals, acquisitions, share buybacks, reverse stock splits and new listings. While stronger earnings and growth plans lifted some stocks, others came under pressure despite positive operational updates or corporate actions.

Neogen Q1 FY27 Results: Revenue Rises 6.5%, Guidance Raised; Stock Falls 3.7%

Neogen Corporation (NASDAQ: NEOG) reported first-quarter fiscal 2027 revenue of $222.8 million, up 6.5% from $209.2 million a year earlier. The company also raised its full-year fiscal 2027 guidance, with revenue now expected at $885 million-$890 million and Adjusted EBITDA at $181 million-$183 million.

Food Safety revenue increased 7.4% to $163.2 million, while Animal Safety revenue rose 4.2% to $59.6 million. Adjusted net income increased to $17.5 million, or $0.08 per share, from $9.5 million, or $0.04 per share, in the year-ago quarter. Adjusted EBITDA also rose to $41.6 million from $35.5 million.

Despite the stronger adjusted earnings and higher guidance, Neogen shares were trading lower during Wednesday’s session. The stock had closed at $11.96 on October 6. On October 7, it opened at $12.61, climbed to a high of $12.92, and subsequently fell to a low of $11.37. As of 12:16 p.m. EDT, NEOG was trading at $11.52, down about 3.7% from the previous close. The stock was therefore trading below its opening level and close to its session low. Historical market data confirms that the previous session ended at $11.96 after an 8.07% decline.

The day’s move represents a swing of $1.55 between the high and low, highlighting considerable volatility following the results. The shares have also remained under pressure after a sharp decline in the previous session, when NEOG fell from an October 5 close of $13.01 to $11.96 on October 6.

Neogen said it remains on track to begin its planned multi-quarter transition of Petrifilm manufacturing to its Lansing facility in November 2026. The company also expects the previously announced sale of its global Genomics business to Zoetis to close by the end of December, subject to regulatory reviews and customary conditions.

Penguin Solutions Shares Rise 14% as Q4 Earnings Beat Estimates, FY27 Outlook Raised

Penguin Solutions Inc. (NASDAQ: PENG) reported fourth-quarter fiscal 2026 results that beat analyst expectations and raised its fiscal 2027 outlook, driven by stronger demand for its AI infrastructure platform. The company posted adjusted earnings per share of $1.00, above the analyst estimate of $0.77, while revenue reached a record $567 million, up 68% year over year and ahead of the $519.9 million consensus estimate.

For fiscal 2027, Penguin Solutions expects adjusted EPS of $4.45 and revenue of approximately $2.43 billion at the midpoint. The revenue outlook implies growth of about 40%, with a range of plus or minus 10 percentage points.

The company reported adjusted operating income of $90 million, up 129% year over year, while adjusted EBITDA rose 115% to a record $93 million. Penguin Solutions also added six new AI Infrastructure data centre customers during the quarter, including four neocloud providers, and secured several major contracts, including a 36,000-GPU AI factory deployment in Norway.

Penguin Solutions shares were trading sharply higher in Wednesday’s session following the results. The stock opened at $67.33, compared with the previous close of $65.63, and climbed to a high of $76.10. It also touched a low of $65.70 during the session.

As of 12:24 p.m. EDT on October 7, PENG was trading at $74.78, up about 13.9% from the previous close and around 11.1% above its opening price. The stock had gained $9.15 from the previous close so far, although it remained below its session high of $76.10.

Constellation Brands Shares Rise 4% After Q2 Earnings Beat Estimates

Constellation Brands Inc. (NYSE: STZ) reported better-than-expected second-quarter fiscal 2027 results, helped by growth in its beer, wine and spirits businesses. Comparable earnings came in at $3.74 per share, up 3% year over year and above the Zacks Consensus Estimate of $3.62. Net sales increased 6% to $2.63 billion, also exceeding the $2.57 billion consensus estimate.

Beer net sales rose 5% to $2.5 billion, supported by a 5.5% increase in shipment volumes. While Modelo Especial and Corona Extra recorded declines in depletions, Pacifico, Victoria and Modelo Chelada delivered growth. The wine and spirits business also improved, with net sales rising 17% to $159.4 million and shipment volumes increasing 15.4%.

Comparable operating income increased 1% to $896.6 million, although the comparable operating margin declined 160 basis points to 34.1%. The company also generated $1.5 billion in operating cash flow and $1.1 billion in free cash flow during the first six months of fiscal 2027.

Constellation Brands reaffirmed its fiscal 2027 comparable earnings guidance of $11.20-$11.90 per share and maintained its outlook for organic net sales growth ranging from a 1% decline to 1% growth.

Despite the earnings beat, the stock was trading higher during Wednesday’s session. STZ opened at $114.34, compared with the previous close of $113.98, and moved to a high of $120.31. The day’s low so far was $114.10.

As of 1:22 p.m. EDT on October 7, Constellation Brands shares were trading at $117.98, up about 3.5% from the previous close and around 3.2% above the opening price. The stock had gained nearly $4 from the previous close so far, although it remained below its session high.

Also Read: What Is the New York Stock Exchange (NYSE)?

Hess Midstream Shares Fall 9% as Chevron Restructuring Cuts 2027 Outlook

Hess Midstream Partners LP (NYSE: HESM) shares came under heavy selling pressure on Wednesday after the company announced a restructuring agreement with Chevron Corp. (NYSE: CVX) that will turn Hess Midstream into an independent, multi-basin operator. The deal includes Hess Midstream acquiring Chevron’s DJ Basin gathering and storage assets and buying out Chevron’s entire equity stake.

Investor sentiment was pressured by the company’s lower earnings outlook. Hess Midstream expects 2027 Adjusted EBITDA of $850 million-$950 million, sharply below its updated 2026 forecast of $1.225 billion-$1.25 billion. The company also plans to keep per-share distributions flat in 2027 after the fourth quarter of 2026 as it adjusts to the lower cash-flow base.

Under the agreement, Hess Midstream will reduce gathering and processing tariffs for Chevron through 2033, while extending commercial agreements to 2045. Chevron also plans to reduce its Bakken drilling activity from three rigs to two by late 2026. Hess Midstream expects leverage to rise to 3.75x-4.0x Adjusted EBITDA in 2027 before gradually moving toward its long-term target.

Hess Midstream shares opened at $36.05, compared with the previous close of $36.78, and fell to a low of $31.99. The session high so far was $36.05.

As of 1:38 p.m. EDT on October 7, HESM was trading at $32.98, down about 10.3% from the previous close and roughly 8.5% below its opening price. The stock had recovered somewhat from its session low but remained sharply lower. Chevron shares were also lower, trading at $204.99, down about 1.3% from the previous close.

SRX Global Shares Rise 4% After $1 Million Stock Deal to Acquire CERo Therapeutics

SRX Global Inc. (NYSE American: SRXH) has agreed to acquire all outstanding shares of CERo Therapeutics from CERo Therapeutics Holdings in a deal that will make the biotechnology company a wholly owned subsidiary. The transaction includes $1 million in SRX common stock, forgiveness of up to $11.67 million in senior secured debt and the assumption of about $1.56 million in specified liabilities.

The parties signed the Stock Purchase Agreement on October 6, 2026. The senior secured debt currently has a balance of about $8.25 million, with the transaction also terminating related security and pledge arrangements.

The deal supports SRX Global’s strategy of expanding through biotechnology acquisitions, while providing CERo with significant debt relief. However, the transaction remains subject to several closing conditions, including preferred stock conversions, required consents and other customary requirements. CERo’s parent also has a 30-day go-shop period to seek a potentially superior proposal, with up to an additional 45 days to complete such a transaction.

SRX Global shares were trading higher in Wednesday’s session. The stock opened at $1.54, compared with the previous close of $1.48, and moved between a low of $1.49 and a high of $1.63.

As of 1:28 p.m. EDT on October 7, SRXH was trading at $1.54, up about 4.1% from the previous close. The shares were unchanged from the day’s opening price and remained about 5.5% below the session high.

Vistra Shares Rise 10% After DOE Announces $4.2 Billion Conditional Nuclear Loan

Vistra Corp. (NYSE: VST) shares climbed sharply on Wednesday after the U.S. Department of Energy announced a conditional loan commitment of up to $4.2 billion to support nuclear plant upgrades in Pennsylvania and Ohio. The financing is expected to fund 433 megawatts of additional nuclear capacity while helping preserve about 4 gigawatts of existing generation.

The investment will support upgrades at Vistra’s Beaver Valley plant in Pennsylvania and its Davis-Besse and Perry plants in Ohio. The projects are expected to increase output from existing facilities without requiring new transmission corridors and could extend plant operations by 20 years beyond their current licences. The DOE commitment also includes an option to finance future uprates at Vistra’s Comanche Peak plant in Texas.

The financing is linked to Vistra’s plans to expand nuclear generation amid rising electricity demand. The company has a 2.6-gigawatt power purchase agreement with Meta that includes capacity from its Perry and Davis-Besse plants, along with additional uprated capacity from the three facilities.

Vistra shares opened at $154.77 on Wednesday, compared with the previous close of $153.72, and rose to a high of $165.61. The session low so far was $154.02.

As of 1:42 p.m. EDT on October 7, VST was trading at $165.32, up about 7.5% from the previous close and 6.8% above the opening price. The stock was trading close to its session high, reflecting the positive market response to the proposed DOE financing.

The loan commitment remains conditional, however, with Vistra required to satisfy technical, legal, environmental and financial conditions before definitive financing documents are completed and funds are provided.

BKV Shares Rise 7% After Securing 1,200 MW Power Generation Equipment Contract

BKV Corporation shares climbed after the company announced that a wholly owned subsidiary had signed an equipment supply contract for approximately 1,200 megawatts of natural gas-fired power generation equipment for a prospective Texas project. BKV also entered into a backstop agreement with a leading investment-grade hyperscaler, which is the intended off-taker for the project. The hyperscaler will reimburse about 90% of BKV’s equipment-related payments through March 31, 2027, reducing the company’s near-term financial exposure. The equipment includes gas turbines, steam turbines, heat recovery steam generators and related systems, with deliveries scheduled to begin in September 2028.

BKV shares were trading at $23.64 as of 1:44 p.m. EDT on October 7, up about 7.2% from the previous close of $22.05. The stock opened at $23.30, rose to a high of $24.34, and fell to a low of $22.94. The current price was about 1.5% above the opening level and remained below the session high.

The agreement also gives BKV the option to terminate the equipment contract after March 31, 2027 if mutually acceptable offtake arrangements are not reached, with no further payment obligations. The company said securing the long-lead equipment supports its strategy of expanding an integrated platform spanning natural gas production, power generation and carbon capture.

Also Read: How to invest in US stocks

Alvotech Shares Fall 2% Despite US Manufacturing Agreement With LOTTE Biologics

Alvotech shares edged lower after the biotechnology company announced a long-term strategic manufacturing agreement with LOTTE Biologics to expand its global supply capacity. Under the agreement, LOTTE Biologics will manufacture drug substance for multiple antibody biosimilar products at its Syracuse, New York, facility for supply to international markets. The facility has 40,000 litres of bioreactor capacity, along with process development and quality-control capabilities. The partnership is expected to expand Alvotech’s US manufacturing footprint and provide additional flexibility as demand for its biosimilar portfolio grows.

Alvotech shares were trading at $6.00 as of 1:45 p.m. EDT on October 7, down about 2.2% from the previous close of approximately $6.14. The stock opened at $6.10, reached a high of $6.14 and touched a low of $5.92. At the current level, the shares were about 1.6% below the opening price and remained close to the session low.

The companies described the arrangement as a long-term partnership that could expand over time. Alvotech said the additional manufacturing capacity complements its existing partnerships and in-house capabilities and should support its pipeline and future product launches. However, commercial supply remains subject to successful technology transfer, manufacturing qualification and required regulatory approvals. The agreement therefore adds manufacturing capacity but does not immediately translate into commercial supply.

Bradbury Capital Shares Jump 47% After Nasdaq Debut Following Business Combination

Bradbury Capital Inc. began trading on Nasdaq under the ticker BBCI on October 7 after completing its previously announced business combination with Technology & Telecommunication Acquisition Corporation. The transaction marks the company’s entry into the US public markets and follows its merger with TETE. Bradbury Capital provides electronic voucher services and digital payment solutions through its subsidiary Super Apps Holding and strategic partnerships across Southeast Asia.

The company also completed a $5 million PIPE investment, with an investor purchasing 625,000 ordinary shares. Following the transaction, the company’s ordinary shares and warrants began trading under the new symbols BBCI and BBCI W, while the former TETE units ceased trading separately. The company said access to US capital markets will support its plans to expand its digital payments platform and pursue new opportunities.

BBCI shares showed a sharp move in their first Nasdaq session. According to market data, the stock was at $14.73, up 47.15%, with trading later shown as suspended. Shares opened at $10.01, matching the previous close, and climbed to a high of $15.25, while the session low stood at $10.01. The stock therefore traded as much as 52% above its opening level before the suspension.

The strong early move came as investors reacted to the completed business combination and the company’s transition to Nasdaq trading. As a newly listed stock, however, the price may remain volatile as trading develops.

DayOne Data Centres Files for Nasdaq IPO Under Ticker DODC

DayOne Data Centres Limited has filed a registration statement with the US Securities and Exchange Commission for a proposed initial public offering of American Depositary Shares, marking a step toward a potential Nasdaq listing. The Singapore-headquartered data centre operator has applied to list its ADSs on the Nasdaq Global Select Market under the ticker symbol DODC. The company has not yet disclosed the number of shares to be offered or the expected price range.

Founded in 2022, DayOne operates data centres across 10 markets in Asia Pacific and Europe, including Singapore, Malaysia, Indonesia, Thailand, Japan, Hong Kong, Finland and Spain. The company is positioning the offering to access US capital markets as demand for data-centre infrastructure continues to expand.

Morgan Stanley, J.P. Morgan, BofA Securities and Citigroup have been appointed as underwriters for the proposed offering. However, the filing does not mean the IPO has been completed. The registration statement remains subject to SEC review and has not yet become effective, while key details such as the offering size and pricing remain undecided.

Because DayOne is not yet publicly traded, there is no current Nasdaq share price or intraday stock performance to report. Trading under DODC would begin only if the IPO becomes effective and the offering is completed. The filing nevertheless puts the data-centre operator on the path toward a US market debut and could provide investors with another listed avenue to gain exposure to the growing data-centre sector.

Rocket Pharmaceuticals Shares Rise 3% After $150 Million Credit Facility

Rocket Pharmaceuticals shares moved higher after the biotechnology company secured a credit facility of up to $150 million from Hercules Capital to support development of its cardiovascular genetic-medicine portfolio. The financing is expected to extend Rocket’s operational cash runway into the third quarter of 2028, with additional drawdowns potentially providing funding into 2029. The company plans to use the proceeds primarily to advance its pivotal Phase II study of RP-A501 for Danon disease.

Rocket drew an initial $35 million at closing, while another $35 million remains available at its option during specified periods. A further $30 million could become available after the company reaches a defined clinical milestone, while the final $50 million tranche requires approval from Hercules Capital’s investment committee. The facility also includes warrants to purchase Rocket common stock.

Rocket Pharmaceuticals shares were trading at $2.57 as of 1:53 p.m. EDT on October 7, up about 3.2% from the previous close of approximately $2.49. The stock opened at $2.45, reached a high of $2.64 and touched a low of $2.42. At the current level, shares were about 4.9% above the opening price and remained below the session high.

The staged financing gives Rocket additional capital while allowing future funding to be tied to clinical progress. The company had $283.7 million in cash, cash equivalents and investments as of June 30, 2026. The financing follows its earlier $180 million agreement to sell a priority review voucher, further diversifying its sources of capital.

Also Read: US Stock Market Timings 

Coffee Holding Shares Rise 18% After $2.5 Million Share Buyback Approval

Coffee Holding shares jumped after the company’s board approved a $2.5 million share repurchase program, allowing the coffee roaster and dealer to buy back outstanding common stock. The company plans to fund the purchases with available cash and future operating cash flow. Repurchases may take place on the open market or through privately negotiated transactions, depending on market conditions and the company’s share price.

Coffee Holding said the program reflects management’s view that its current stock price does not fully reflect the company’s underlying fundamentals. CEO Andrew Gordon also pointed to a strong balance sheet and improving results, supported by efforts to expand gross margins and eliminate operational redundancies. The buyback may be suspended or discontinued at any time, and purchases could also be made under a Rule 10b5-1 plan.

Coffee Holding shares were trading at $4.69 as of 1:53 p.m. EDT on October 7, up about 17.6% from the previous close of approximately $3.99. The stock opened at $4.17, climbed to a high of $4.75 and touched a low of $4.14. At the current price, shares were about 12.5% above the opening level and remained close to the session high.

The sharp move came as investors responded to the newly authorised buyback and management’s positive assessment of the company’s financial position. Coffee Holding has operated since 1971 and sells proprietary coffee brands while supplying roasted and blended coffee to wholesalers and retailers in the US and Canada.

SU Group Shares Rise 2% After 1-for-6 Reverse Stock Split Takes Effect

SU Group Holdings shares moved higher on Wednesday after the company’s 1-for-6 reverse stock split took effect on October 7. The share consolidation combines every six Class A ordinary shares into one new share, while the stock continues to trade on Nasdaq under the existing ticker SUGP. The company said the move reduced its issued and outstanding ordinary shares from approximately 9.01 million to about 1.50 million. No fractional shares will be issued, with fractional entitlements rounded up to the nearest whole share.

The reverse split became effective at 12:01 a.m. EDT on October 7, with SUGP beginning trading on a post-split basis at the market open. The company said the consolidation is expected to continue without disrupting Nasdaq trading, subject to continued compliance with listing requirements.

SU Group shares were trading at $2.65 as of 1:55 p.m. EDT on October 7, up about 1.9% from the previous close of approximately $2.60. The stock opened at $2.51, reached an intraday high of $2.70 and touched a low of $2.46. At the current price, shares were about 5.6% above the opening level and remained below the session high.

The company said outstanding options, warrants and other convertible securities will also be adjusted according to the 1-for-6 ratio. The reverse split changes the share structure but does not, by itself, change the underlying value of shareholders’ holdings.

Green Circle Shares Fall 50% as 1-for-6 Share Consolidation Takes Effect

Green Circle Decarbonize Technology shares fell sharply on Wednesday as the company’s previously announced 1-for-6 share consolidation took effect. The consolidation became effective at 12:01 a.m. EDT on October 7, with GCDT beginning trading on a split-adjusted basis at the NYSE American open. The company said the move is intended to increase its per-share trading price and support compliance with continued listing requirements. The stock continues to trade under the ticker GCDT.

The share consolidation combines every six existing Class A ordinary shares into one new share, with no fractional shares issued. The company said fractional entitlements will be rounded up to the next whole share. Outstanding options, warrants and other convertible securities will also be adjusted to reflect the consolidation.

GCDT shares were trading at $0.71 as of 1:59 p.m. EDT on October 7, down about 50.3% from the previous close of approximately $1.43. The stock opened at $1.03, climbed to an intraday high of $1.10 and fell to a low of $0.67. At the current level, shares were about 31.1% below the opening price and close to the session low.

The steep decline came on the same day the company also highlighted plans to enter the AI data-centre cooling market with proprietary ultra-low-energy liquid-cooling solutions. Green Circle said it is conducting technical discussions and preliminary evaluations with industry participants as it develops the technology.

Helmerich & Payne Shares Slip 1% Despite Strong Fiscal Q4 Operational Update

Helmerich & Payne shares edged lower on Wednesday after the drilling contractor said it expects strong operational and segment financial results for the fourth quarter of fiscal 2026. The company expects direct margins across its North America Solutions, International Solutions and Offshore Solutions businesses to come in at or near the high end of its previously issued guidance ranges.

North America Solutions’ average rig count is also expected to be near the upper end of its guidance, while International Solutions and Offshore Solutions activity is expected around the midpoint of their respective ranges. H&P highlighted particularly strong performance from its International Solutions segment, where quarterly direct margins are expected to reach about $45 million. The company also maintained all other financial guidance issued in August.

Helmerich & Payne shares were trading at $39.35 as of 2:06 p.m. EDT on October 7, down about 1.4% from the previous close of approximately $39.91. The stock opened at $39.90, reached an intraday high of $40.44 and touched a low of $39.11. At the current price, shares were about 1.4% below the opening level and remained near the session low.

Looking ahead, management expects stronger overall direct margins in fiscal 2027, supported by customer discussions and contracting activity. H&P expects robust North American activity and growth in Latin America to partly offset near-term reductions in Middle East activity. The company also reaffirmed its goal of reaching roughly 1x net debt to adjusted EBITDA by the end of 2027 while maintaining its base dividend.

October 7 trading highlighted how sharply investors can respond to company-specific developments. Strong earnings, raised guidance, new financing and strategic agreements supported gains in several stocks, while weaker outlooks and corporate restructuring weighed on others. Share consolidations and newly completed business combinations also triggered notable price movements, particularly in smaller companies. With the US market still in progress, these intraday moves may change before the closing bell. Investors should therefore distinguish between immediate market reactions and the longer-term impact of each development